Table 3.

Age-related survival and acute myeloid leukemia (AML) evolution in myelodysplastic syndrome (MDS) patients within International Prognostic Scoring System (IPSS) subgroups.*

Median Survival (yr)
No. of PtsLowInt-1Int-2High
Total pts.: No. (%) 816 267 (33%) 314 (38%) 176 22%) 59 (7%) 
  5.7 3.5 1.2 0.4 
Age ≤ 60 yr 206 (25%) 11.8 5.2 1.8 0.3 
> 60 yr 611 4.8 2.7 1.1 0.5 
≤ 70 yr 445 (54%) 9.0 4.4 1.3 0.4 
> 70 yr 371 3.9 2.4 1.2 0.4 
Median Survival (yr)
No. of PtsLowInt-1Int-2High
Total pts.: No. (%) 816 267 (33%) 314 (38%) 176 22%) 59 (7%) 
  5.7 3.5 1.2 0.4 
Age ≤ 60 yr 206 (25%) 11.8 5.2 1.8 0.3 
> 60 yr 611 4.8 2.7 1.1 0.5 
≤ 70 yr 445 (54%) 9.0 4.4 1.3 0.4 
> 70 yr 371 3.9 2.4 1.2 0.4 
25% AML Evolution (yr)
No. of PtsLowInt-1Int-2High
Abbreviations: AML, acute myeloid leukemia; pts., patients; NR, not reached. 
* Modified from Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088. 
Total pts.: No. (%) 759 235 (31%) 295 (39%) 171 (22%) 58 (8%) 
  9.4 3.3 1.1 0.2 
Age ≤ 60 yr 187 (25%) > 9.4 (NR) 6.9 0.7 0.2 
> 60 yr 572 9.4 2.7 1.3 0.2 
≤ 70 yr 414 (55%) > 9.4 (NR) 5.5 1.0 0.2 
> 70 yr 345 > 5.8 (NR) 2.2 1.4 0.4 
25% AML Evolution (yr)
No. of PtsLowInt-1Int-2High
Abbreviations: AML, acute myeloid leukemia; pts., patients; NR, not reached. 
* Modified from Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088. 
Total pts.: No. (%) 759 235 (31%) 295 (39%) 171 (22%) 58 (8%) 
  9.4 3.3 1.1 0.2 
Age ≤ 60 yr 187 (25%) > 9.4 (NR) 6.9 0.7 0.2 
> 60 yr 572 9.4 2.7 1.3 0.2 
≤ 70 yr 414 (55%) > 9.4 (NR) 5.5 1.0 0.2 
> 70 yr 345 > 5.8 (NR) 2.2 1.4 0.4 
Close Modal

or Create an Account

Close Modal
Close Modal